Neogen (NASDAQ:NEOG) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Neogen (NASDAQ:NEOG) from a buy rating to a hold rating in a report issued on Saturday.

NEOG has been the topic of a number of other research reports. CJS Securities raised Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, December 10th. Piper Sandler set a $6.50 price objective on Neogen and gave the stock a “neutral” rating in a research report on Thursday, October 16th. Guggenheim reiterated a “buy” rating and issued a $12.00 target price (up previously from $8.00) on shares of Neogen in a research report on Friday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Neogen in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.50.

Neogen Price Performance

NEOG stock opened at $9.62 on Friday. The company’s 50-day moving average price is $6.66 and its two-hundred day moving average price is $5.89. The firm has a market cap of $2.09 billion, a P/E ratio of -3.47 and a beta of 1.96. The company has a quick ratio of 2.26, a current ratio of 3.91 and a debt-to-equity ratio of 0.38. Neogen has a 12 month low of $3.87 and a 12 month high of $12.98.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings results on Thursday, January 8th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. The company had revenue of $224.69 million during the quarter, compared to the consensus estimate of $208.50 million. Neogen had a negative net margin of 68.47% and a positive return on equity of 2.14%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.11 EPS. On average, analysts anticipate that Neogen will post 0.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Neogen

Several large investors have recently bought and sold shares of the company. Savant Capital LLC acquired a new stake in shares of Neogen during the second quarter valued at about $50,000. Tudor Investment Corp ET AL bought a new position in Neogen in the 3rd quarter valued at approximately $62,000. Coldstream Capital Management Inc. acquired a new stake in Neogen during the 3rd quarter worth approximately $64,000. Cresset Asset Management LLC bought a new stake in Neogen during the 2nd quarter worth approximately $53,000. Finally, Evergreen Capital Management LLC acquired a new position in Neogen in the 2nd quarter valued at approximately $56,000. 96.73% of the stock is currently owned by institutional investors.

Neogen News Summary

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Q2 results beat consensus on key metrics and management raised FY2026 revenue guidance to $845–$855M (above consensus), signaling progress on a turnaround; investors liked the combination of revenue outperformance and guidance lift. Neogen Raises Guidance as Cost-Cutting Takes Hold
• Positive Sentiment: Market reaction: the stock spiked sharply (reports note moves >30%) after the earnings and guidance, reflecting renewed investor optimism about revenue growth and cost actions. Why Neogen Stock Blasted More Than 31% Higher Today
• Positive Sentiment: Heavy bullish options activity and call buying accompanied the move (unusually large call volume), suggesting speculative and institutional interest in the near-term upside. Neogen Posts Strong Q2 Earnings
• Neutral Sentiment: Analyst & institutional context: a small number of upgrades and divergent price targets mean consensus is still forming; some funds have been reallocating positions into/out of NEOG. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Underlying GAAP metrics remain mixed: some reports show the company recorded operating and net losses and weaker operating cash flow in the quarter (contrast between adjusted EPS and GAAP results creates ambiguity about sustainable profitability). That tempers the bullish narrative and raises execution risk. QuiverQuant Q2 Earnings Summary

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.